Skip to Content
Morningstar

Qiagen NV QGEN

Morningstar Rating
Unlock
Stock XNYS Rating as of
$40.00 +0.53 (1.34%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Qiagen's Operating Results Stabilizing After the Pandemic

Julie Utterback

Qiagen aims to help scientists and caregivers use biological samples to identify and solve problems related to DNA, RNA, and proteins, which should remain in demand even as the pandemic transitions into an endemic situation, albeit probably at a moderately lower rate. Qiagen's roots are in products that help scientists prepare biological samples for various experiments, and sample preparation products still account for about 35% of sales. Qiagen remains a key leader in this niche, and we expect Qiagen to continue to invest to maintain or improve in that business in the long run.

Read Full Report

Price vs Fair Value

View History
QGEN is trading at a 24% discount.
Price
$39.47
Fair Value
$94.00
Uncertainty
Medium
1-Star Price
$42.20
5-Star Price
$94.50
Economic Moat
Jmwj
Capital Allocation
Hmyqljcj

Bulls Say, Bears Say

Bulls

Qiagen’s long-term growth prospects in the life science and diagnostic markets will not dissolve just because the pandemic turns into an endemic situation.

Bears

Competitive threats in Qiagen's chosen fields, particularly diagnostics, may always remain high given the risk of disruptive innovation from new and established organizations.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QGEN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$39.47
Day Range
$39.64–40.14
52-Week Range
$35.81–49.18
Bid/Ask
$39.17 / $41.63
Market Cap
$8.85 Bil
Volume/Avg
1.1 Mil / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
18.64
Price/Sales
4.49
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Qiagen NV offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Core
Total Number of Employees
6,000
Website
https://www.qiagen.com

Competitors

Valuation

View More
Metric
QGEN
ILMN
DHR
Price/Earnings (Normalized)
 18.64135.2827.74
Price/Book Value
 2.293.263.27
Price/Sales
 4.494.137.35
Price/Cash Flow
 13.6632.7425.52
Price/Earnings
QGEN
ILMN
DHR

Financial Strength

Metric
QGEN
ILMN
DHR
Quick Ratio
 1.461.141.18
Current Ratio
 1.991.661.68
Interest Coverage
 7.57−14.2617.58
Quick Ratio
QGEN
ILMN
DHR

Profitability

Metric
QGEN
ILMN
DHR
Return on Assets (Normalized)
 7.71%0.03%5.68%
Return on Equity (Normalized)
 13.14%0.06%9.47%
Return on Invested Capital (Normalized)
 8.51%0.21%6.69%
Return on Assets
QGEN
ILMN
DHR
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncRpppvmshhMnfxs$206.7 Bil
DHR
Danaher CorpLpfttsfyQmvgf$175.0 Bil
IQV
IQVIA Holdings IncNkyvqvcHpjrz$41.3 Bil
IDXX
IDEXX Laboratories IncRyfqnkwtrcXdyqqd$39.7 Bil
A
Agilent Technologies IncThtrgmfqZsnv$38.8 Bil
MTD
Mettler-Toledo International IncMgpvtpzpmMxnrhy$25.5 Bil
ICLR
Icon PLCRygzhzhdZgfmplp$24.1 Bil
ILMN
Illumina IncWlmnqzhfVwvhkwl$18.6 Bil
WAT
Waters CorpTyvfryfrDnz$18.0 Bil
LH
Laboratory Corp of America HoldingsQcyzvxvldlHcbfmk$16.8 Bil

Sponsor Center